Skip to main content

INCB 24360-208 A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

July 13, 2018

End Date

August 23, 2019
 

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

July 13, 2018

End Date

August 23, 2019